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Anaplastic thyroid carcinoma (ATC) is one of the most
malignant human neoplasms and has a grave prognosis. This
study gives an update on our experience with this unusual
neoplasm, with specific focus on the response to various
treatment modalities. Forty-seven patients with histologically
proven ATCs were enrolled (19 men, 28 women; mean age,
62.8 years). This number represents 1.5% among a total of
3,088 thyroid cancers treated between 1977 and 2002. The
mean tumor diameter was 8.8 cm, and 22 patients had distant
metastasis. Extrathyroidal extension was seen in 26 (89.7%)
of the cases that underwent surgery. Treatment modalities
adopted could be classified into 5 groups: Group 1, biopsy
only; Group 2, biopsy and chemoradiotherapy; Group 3,
debulking only; Goup 4, debulking and chemoradiotherapy;
Group 5, complete excision and chemoradiotherapy. Survival
was calculated from the time of diagnosis, and comparisons
of survival were done by log-rank analysis. The mean survival
was 4.3 months (range, 1.0-21 months). The mean survival
based on treatment modalities were as follows: Group 1 (n =
10), 2.1 months, Group 2 (n = 8); 3.6 months; Group 3 (n =
7), 3.0 months; Group 4 (n = 14), 3.5 months, Group 5 (n =
8), 9.4 months. There was no significant difference in survival
time between the various types of treatment modalities. Even
though a small improvement in survival was observed with
complete excision and aggressive multimodality therapy,
nearly all ATCs remain unresponsive to ongoing treatment
modalities and as such, present a therapeutic dilemma. A more
effective treatment regimen should be sought in order to
improve survival.
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INTRODUCTION
Anaplastic thyroid carcinoma (ATC) is one of
the most aggressive and rapidly progressing
human carcinomas resulting in fatal prognosis.1
ATCs characteristically manifest suddenly as a
rapidly growing thyroid mass, and most are
known to arise from a pre-existing malignant or
benign thyroid disease.2,3 Surgical approaches are
generally not appropriate because this disease
usually presents as a huge cancerous mass in-
vading adjacent tissues, with distant metastasis at
the time of diagnosis. An aggressive treatment
may be attempted for the tumors at an early stage,
but curative therapy has been reported to be
almost impossible.4 Although the multimodality
treatment approach is reported to be necessary for
this condition, there are only few reports regard-
ing the efficacy of surgery with adjuvant therapies
in ATC.5 Moreover, as the incidence of ATC is
very low, there are only a few studies pertaining
to its accurate diagnosis and clinical course after
therapy.
In this study, the authors report on 47 cases of
ATCs over a 26-year period. We describe herein
the retrospective analysis of various treatment
results after surgery, including multimodal treat-
ment, and ascertain the efficacy of these mo-
dalities.
MATERIALS AND METHODS
From January 1977 to December 2002, 47
patients with ATC, representing 1.5% of 3,088
total patients with thyroid carcinoma, who under-
went surgery in the Department of Surgery,
Yonsei University College of Medicine were
enrolled in this study. These patients' records
were retrospectively analyzed with respect to
clinical manifestations, size of tumor, extent of
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disease, distant metastasis, pathologic findings,
treatment modality, and cause of death. The out-
come of the multimodal treatment method was
also evaluated.
Surgical therapy for ATC was comprised of
radical resection for patients with completely
resectable tumors, palliative resection for tumor
debulking purposes, and excisional biopsy only
for unresectable cases.
Adjuvant radiotherapy or radiotherapy as a
primary mode of treatment was initiated in 34
patients, and consisted of the conventional 2 Gy
per day for a total dose of 50-60 Gy. The hyper-
fractionated radiation therapy followed the pro-
tocol of Kim and Leeper,6 and consisted of admi-
nistration of low-dose adriamycin (10 mg/m2 per
week) given intravenously one and half hours
before initiation of radiotherapy, and then 1.6 Gy
radiotherapy twice a day at 4-5 hour intervals for
a total of 57.6 Gy.
Anticancer chemotherapy was administered in
22 patients as part of the multimodal treatment
with radiotherapy, with adriamycin forming the
basis of the regimen. Adriamycin only was admi-
nistered to 15 patients, while the remaining 7
patients received a combination of adriamycin
and other chemotherapeutic agents such as 5-FU,
cisplatinum, cyclophosphamide, bleomycin, mito-
mycin, taxol, and retinoic acid.
The patients were divided into 5 groups ac-
cording to the differing modes of therapies they
received, and the outcomes were analyzed. The
groups were: Group 1, excisional biopsy only;
Group 2, chemotherapy and radiation therapy
after excisional biopsy only; Group 3, palliative
resection only; Group 4, chemotherapy and
radiation therapy after palliative resection; and
Group 5, chemotherapy and radiation therapy
after complete radical resection (Table 1).
RESULTS
The mean age of the patients at the time of ATC
diagnosis was 62.8 years (range, 19-84 years).
There were 19 male and 28 female patients,
yielding a ratio of 1:1.5. Most patients (46 cases,
97.9%) presented with a rapidly growing anterior
neck mass as the initial presenting symptom. In
16 patients (34%) the presenting symptom was
sudden enlargement of a previously existing thy-
roid mass. Two of these patients had a history of
surgery for papillary thyroid carcinoma. Other
symptoms that were present among the remaining
patients were dyspnea, hoarseness, dysphagia,
weight loss, and the restriction of neck motion.
The mean duration of disease was 2.6 months
(range, 15 days-12 months). The mean diameter of
the thyroid mass at the time of diagnosis was 8.8
cm (range, 2 - 20 cm). There were 25 patients in
whom the lesion was confined to the neck,
however, all of them showed invasion into ad-
jacent tissues and nodal metastasis in the neck.
Twenty-two patients presented distant metastasis
at the time of initial diagnosis. Distant metastases
were comprised of 10 cases of lung metastasis,
and 8 cases which showed both lung and bone
metastases. Two patients demonstrated both lung
Table 1. Patient Group by Treatment Modality
Group n Treatment modality
Inoperable 18
Group 1 10 Biopsy only
Group 2 8 Biopsy + CRT
Operable 29
Group 3 7 Debulking only
Group 4 14 Debulking + CRT
Group 5 8 Excision + CRT
CRT, combined chemo-radiation therapy.
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and mediastinal metastases, and there was 1 case
each of brain and mediastinal metastasis.
The most common histological type was giant
cell type in 13 patients, followed by 10 cases of
spindle cell type, 7 cases of combined giant cell
and spindle cell type, and 1 case of epidermoid
type histology. In the remaining 16 cases, the
precise histological type could not be ascertained.
In fourteen patients, ATCs were combined with
differentiated thyroid carcinoma, consisting of 6
cases of papillary carcinoma and 6 cases of fol-
licular carcinoma. In one case both papillary and
follicular types were present, and the last case
showed both papillary and epidermoid com-
ponents.
Of the 47 total patients, some kind of surgical
treatment was possible in 29 (61.7%). Among
them, only 8 patients (17.0%) underwent radical
surgery, while the remaining 21 (44.7%) under-
went palliative surgery, and adjuvant therapies
were selected in order to alleviate symptoms such
as dyspnea and dysphagea.
The mean survival time in Group 1, from the
time of diagnosis to death, was 2.1 months. For
Groups 2, 3, 4, and 5, survival times were 3.6
months, 3.0 months, 3.5 months, and 9.4 months,
respectively. A longer survival period was ob-
served in Group 5 than that of Group 1, but there
was no statistical difference between the two
groups (Table 2).
In Group 5, although the mean survival was 9.4
months, most patients showed relatively short
survival times, as the exclusion of 2 cases gave a
mean of 4.8 months (range, 1-7 months). The two
patients who survived for longer periods didn't
show any distinctive clinical features compared to
the others.
Overall, most of the patients demonstrated
rapid disease progression and distant metastasis,
despite the various modes of therapy. The most
frequent organ of metastasis was the lung, while
frequent metastatic lesions were also observed in
the bones and mediastinum (Table 3). The rate of
distant metastasis at the time of diagnosis was
Table 3. Distant Metastases
Site No. at initial examination (%) No. of overall metastases (%)
Lung
Mediastinum
Brain
Lung + Bone
Lung +Mediastinum
Bone + Mediastinum
10 (21.3)
1 (2.1)
1 (2.1)
8 (17.0)
2 (4.3)
0 (0)
12 (25.5)
2 (4.3)
1 (2.1)
9 (19.2)
6 (12.8)
1 (2.1)
Total (%) 19 (46.8) 31 (66.0)
Table 2. Survival Outcome by Treatment Modality
Group n
Survival (months)
Mean Median Range
1
2
3
4
5
10
8
7
14
8
2.1
3.6
3.0
3.5
9.4
2.0
3.0
3.0
3.0
6.0
1.0-5.0
2.0-7.0
1.0-5.0
2.0-9.0
5.0-21.0
Total 47 4.3 3.0 1.0-21.0
No significant difference between any of the groups (p > 0.05).
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46.8%, but this rate increased to 66.0% by the final
count.
For all patients, the mean period of survival
was 4.3 months (range, 1-21 months), and the
most common cause of death was airway
obstruction due to locally advanced disease and
systemic metastasis in 32 patients, followed by
distant metastasis in 14 patients.
DISCUSSION
Small ATC tumors that are discovered inciden-
tally have been reported to have a more favorable
prognosis, and those that are confined to the neck
also show a better prognosis compared to tumors
with distant metastasis.7,8 However, according to
the AJCC staging system, ATCs at any size are
assigned to stage IV disease;9 all present frequent
metastasis and invasion, despite treatment,
leading to death, and thus have a very poor pro-
gnosis. Until recently, no definite risk factors for
this disease had been identified.10,11
A single mode of therapy, whether it be sur-
gery, chemotherapy or radiotherapy, fails to af-
ford significant, favorable treatment outcomes.
While multimodal approaches may enhance treat-
ment responses to a small degree, the imple-
mentation of these modalities is often impractical,
as many patients are old and unable to tolerate
the intensity of the treatments; consequently, their
disease progresses rapidly even during therapy.12
As in many other types of carcinomas, radical
resection for ATC may be the mainstay as far as
mode of therapy, but surgery itself is seldom
possible due to extensive local invasion and
distant metastasis at the time of diagnosis.8,9,13,14 In
this study, radical surgery was performed in only
8 patients (17.0%). There are conflicting data
regarding the effect of the extent of surgery for
ATC on survival. Some authors have reported
improved survival rates in patients with small
tumors who were candidates for radical surgery
over those for patients who received palliative
resection.15-17 Conversely, most other authors are
of the opinion that survival is not increased,
regardless of the type of surgery undertaken.18,19
Furthermore, even with aggressive surgical ther-
apy for those invasive ATCs, there is no evidence
of decreased recurrence rates, while the post-sur-
gical morbidity rates increase.8 Therefore, aggres-
sive surgical resection involving vital organs such
as laryngectomy or tracheal resection for locally
invasive ATCs are not appropriate. In this report,
radical surgical approaches for ATCs with even an
early stage of invasion did not produce greater
survival benefits compared to other treatment
modalities.
One chemotherapeutic agent that seems to
demonstrate some anti-cancer effect against ATC
is adriamycin, which is more effective when admi-
nistered in combination than as a single agent,
and is also known to act synergistically with ra-
diotherapy.10 A current treatment modality com-
monly employed is the combination of adriamycin
and cisplatin administration with hyperfraction-
ated radiation therapy. There have been a number
of reports to date which suggest that the post-
operative administration of adriamycin and
hyperfractionated radiation therapy increase the
local control rate and prolong survival,6 while
others have suggested that thyroidectomy after
neoadjuvant chemotherapy may be more fea-
sible.10 In contrast, we were not able to observe
any benefit of chemotherapy, whether it was done
by neoadjuvant or adjuvant means, nor any in-
crease in survival. These results are in agreement
with the reports which found no improvement in
survival despite the combination of chemotherapy
and radiotherapy, and which concluded that the
role of chemotherapy, preoperatively or post-
operatively is equivocal.20,21
It has been acknowledged that the efficacy of
radiotherapy for ATC is largely unsatisfactory,
and in particular, conventional radiotherapy has
not seemed to have any therapeutic effects at
all.19,22 Despite these disappointing results of con-
ventional radiotherapy, hyperfractionated radia-
tion therapy and combined chemotherapy has
been suggested as a multimodal treatment ap-
proach to improve survival rates,6,15,16 though
some disagree.12,22,23 Our study showed a mean
survival of only 3.5 months after this combined
mutimodal treatment for patients with unre-
sectable disease, while the same adjuvant treat-
ment after radical surgery tended to show im-
proved survival. However, the difference was not
significant. These results demonstrate that the
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combination of hyperfractionated radiation ther-
apy with chemotherapy does not afford signifi-
cantly improved survival results. The modality
may be useful as an adjuvant mode of therapy in
improving the outcome for patients after radical
resection. However, this has not been confirmed
statistically and therefore, further studies and
long-term investigation should be done.
Many studies have addressed the question of
risk factors for survival in ATC, and have shown
that for patients less than 45 years of age with
localized disease in the neck, and who receive
aggressive surgical therapy such as thyroidectomy
followed by radiotherapy and chemotherapy,
there is improvement in survival. However, the
results of this study showed no significant
difference in survival regardless of the types of
treatment modalities used, and there was no
influence of clinicopathological characteristics. In
our series, only 2 patients survived for relatively
longer periods of time (11 months, 21 months);
these numbers are insufficient to draw any mean-
ingful conclusions.
The dismal treatment results for ATCs have
stimulated the investigation of new therapeutic
methods with improved outcomes. There have
been a number of trials of new materials or
therapeutic methods which have already turned
out to be ineffective or too toxic to clinically
apply, such as exogenous interleukin-6, transfec-
tion of human thyroperoxidase gene in tumor
cells, and imatineb mesylate monotherapy.24 In
recent studies, some trials were partially suc-
cessful or promising in vitro or vivo. Examples
include the use of bone morphogenic protein
(BMP-7) by inhibiting cycli-dependent kinase ac-
tivity, histon deacetyase inhibitors with increased
apoptosis, an E1B 55-kDa gene-defective adeno-
virus (ONYX-015) with adriamycin and paclitaxel,
restoration of p53 expression in ATC cells, gene
therapy using the interleukin-12 gene in BALB/C
(nu/nu) mice, and re-differentiation therapy using
retinoids.25-29 Although observations may suggest
that some of these methods have a potential thera-
peutic effect on ATCs or can act as an adjunct to
another primary treatment modality, their efficacy
and safety have not yet been ascertained in
human trials, and further confirmation through
in-depth studies is required.
ATCs are accompanied by unfavorable pro-
gnosis, irrespective of mode of therapy, and thus
present a serious dilemma to the patient as well
as the physician. Therefore, detailed, prospective
investigations are direly needed to elucidate an
effective mode of treatment.
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